RxDoctor Payments Data

Donald McFarland, DO

Internal Medicine · Bridgeville, PANPI 1992778104

Payments from drug & device makers

$22,786in general payments, 2019–2025

Across 1,425 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • GSK$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$22,66799%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$3,129
GSK165$2,716
AstraZeneca94$1,931
Pfizer119$1,869
Novo Nordisk102$1,495
Lilly USA, LLC74$1,223
Takeda Pharmaceuticals U.S.A., Inc.57$886
Amgen(2 entities)52$708
Johnson & Johnson46$694
Boehringer Ingelheim43$668
E.r. Squibb & Sons, L.L.C.32$602
Bayer35$557
Merck42$541
Sanofi-aventis U.S. LLC33$500
Abbott38$436
Novartis27$364
Astellas Pharma US Inc30$363
Amarin Pharma, Inc.18$313
Vanda Pharmaceuticals Inc.13$265
Otsuka America Pharmaceutical, Inc.12$223
Biohaven Pharmaceuticals, Inc.15$217
Biohaven Pharmaceutical Holding Company Ltd.13$188
Esperion Therapeutics, Inc.15$184
Aimmune Therapeutics, Inc.9$175
Viatris Specialty LLC9$157
Nestle Healthcare Nutrition Inc.9$154
Mylan Specialty L.p.6$133
Exact Sciences7$129
Teva Pharmaceuticals USA, Inc.7$125
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$112
Axsome Therapeutics, Inc.5$109
Philips North America LLC5$109
Phathom Pharmaceuticals, Inc.6$109
Xeris Pharmaceuticals, Inc.5$106
Averitas Pharma Inc.3$87
Kowa Pharmaceuticals America, Inc.5$74
Eisai Inc.5$70
Verona Pharma, Inc.3$69
Sunovion Pharmaceuticals Inc.7$69
Azurity Pharmaceuticals, Inc.3$56
Amneal Pharmaceuticals LLC2$53
Arbor Pharmaceuticals, Inc.2$53
Biogen3$48
Sumitomo Pharma America, Inc.3$48
Dermira, Inc.2$47
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$45
Sanofi Pasteur Inc.2$41
Medtronic2$39
Corcept Therapeutics2$37
Si-bone, Inc.2$36
Corium, LLC2$35
Daiichi Sankyo Inc.2$34
Hikma Pharmaceuticals USA2$33
Dexcom, Inc.2$33
Pulmonx Corporation1$30
Avanir Pharmaceuticals, Inc.2$30
Irhythm Technologies, Inc.1$28
Idorsia Pharmaceuticals US Inc1$24
Boston Scientific1$24
Dynavax Technologies Corporation1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,786 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,373
Medicare patients
246
Services billed
2,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$204,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter192$137,612
OzempicSemaglutide77$99,409
JardianceEmpagliflozin99$87,406
JanuviaSitagliptin Phosphate71$64,684
FarxigaDapagliflozin Propanediol59$64,609
XareltoRivaroxaban41$53,249
TradjentaLinagliptin34$37,100
MyrbetriqMirabegron44$34,897
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$32,049
EntrestoSacubitril/Valsartan27$28,259
Breo ElliptaFluticasone/Vilanterol48$26,606
ProliaDenosumab15$26,096
MounjaroTirzepatide21$23,312
TrulicityDulaglutide12$23,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$1,869$208,400223 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,716$196,268308 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$668$144,380165 claims
Novo NordiskOzempic$1,495$99,40977 claims
MerckJanuvia, Janumet Xr, Janumet$541$87,595102 claims
AstraZenecaFarxiga, Symbicort$1,931$68,90971 claims
Johnson & JohnsonXarelto$694$53,24941 claims
Lilly USA, LLCMounjaro, Trulicity$1,223$46,32333 claims
Astellas Pharma US IncMyrbetriq$363$34,89744 claims
NovartisEntresto$364$28,25927 claims
AmgenProlia$708$26,09615 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$886$17,90718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bridgeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →